Unraveling the Decline: Search for Factors Behind the Trend in Parkinsons Disease Incidence Rates: A Cohort Study of German Health Claims Data

Sporadic Parkinson's disease (PD) is the second most common neurodegenerative disease in older age. Recent studies have led to a debate regarding trends in incidence and prevalence. We aimed to investigate age-specific incidence rates of PD and possible explanations for the observed trend in Germany by studying two randomly selected longitudinal cohorts, each consisting of 250,000 individuals aged 50 and above. We started observing them at the beginning of 2004 and 2014, and followed them through the end of 2009 and 2019, respectively. We compared age-specific incidence rates for both cohorts and performed Cox regression models to calculate the hazard ratios (HR) of PD in the second period compared with the first period ten years earlier, adjusted for age, sex, and several prodromal factors, comorbidities, and risk factors of PD. For each age-group in men and women, we found lower age-specific PD incidence rates in the second period, except for the lowest age-group (50-54) in men. Cox regression analysis demonstrated an overall 20% risk reduction of PD incidence (HR=0.80, 95% confidence interval [0.75-0.86]). Mean age at diagnosis increased in men (+1.98 years) and women (+0,87 years). Stepwise adjustment for prodromal symptoms, comorbidities, and risk factors revealed a 22%-49% risk reduction of PD incidence. Sensitivity analysis considering the competing event of death showed a 48% risk reduction (HR=0.52 [0.48-0.56]), demonstrating the independence of the time trends from changes in death rates. In conclusion, our data show that the risk of PD has decreased over time, and that this decrease is independent of factors such as changes in death rates, age structure, sex, motor and sensory impairments, sleep and psychiatric conditions, comorbidities, and specific risk factors.

[1]  C. Tanner,et al.  Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. , 2023, JAMA neurology.

[2]  C. Tanner,et al.  Trichloroethylene: An Invisible Cause of Parkinson’s Disease? , 2023, Journal of Parkinson's disease.

[3]  S. K. Van Den Eeden,et al.  Incidence of Parkinson disease in North America , 2022, NPJ Parkinson's disease.

[4]  M. Akmatov,et al.  Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease , 2022, JAMA neurology.

[5]  D. Berg,et al.  Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease , 2022, Neurology.

[6]  A. Schrag,et al.  [Trends in Prevalence of Parkinson's Disease in German General and Neurological Practices from 2010 to 2019]. , 2022, Fortschritte der Neurologie-Psychiatrie.

[7]  P. Timpel,et al.  [Treatment practice of patients with Parkinson's disease in Saxony : A secondary data-based analysis of utilization in the observation period 2011-2019]. , 2022, Der Nervenarzt.

[8]  Hyunwoong Ko,et al.  Association between Residential Greenness and Incidence of Parkinson’s Disease: A Population-Based Cohort Study in South Korea , 2022, International journal of environmental research and public health.

[9]  Zachary D. Wallen,et al.  Oral ingestion of the environmental toxicant trichloroethylene in rats induces alterations in the gut microbiome: relevance to idiopathic Parkinson’s disease , 2022, bioRxiv.

[10]  A. Elbaz,et al.  Pesticides expenditures by farming type and incidence of Parkinson disease in farmers: a French nationwide study. , 2021, Environmental research.

[11]  Zhe-bin Yu,et al.  Air pollution, surrounding green, road proximity and Parkinson's disease: a prospective cohort study. , 2021, Environmental research.

[12]  B. D. De Miranda,et al.  The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson’s disease , 2020 .

[13]  L. G. Vu,et al.  Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.

[14]  M. Brauer,et al.  Road proximity, air pollution, noise, green space and neurologic disease incidence: a population-based cohort study , 2020, Environmental health : a global access science source.

[15]  Kyoung-Sae Na,et al.  Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea , 2019, BMC Public Health.

[16]  A. Khundakar,et al.  Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant α-synuclein mice , 2019, Neuroscience Letters.

[17]  F. Vaglini,et al.  Parkinson’s disease and light: The bright and the Dark sides , 2019, Brain Research Bulletin.

[18]  P. Taba,et al.  Incidence and Mortality of Parkinson’s Disease in Estonia , 2019, Neuroepidemiology.

[19]  A. Kopp,et al.  Time Trends of the Incidence, Prevalence, and Mortality of Parkinsonism , 2019, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[20]  B. Bloem,et al.  The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.

[21]  Vinay Goyal,et al.  Parkinson's disease: A review , 2018, Neurology India.

[22]  Eyal Oren,et al.  Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, The Lancet. Neurology.

[23]  A. Heintz‐Buschart,et al.  The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder , 2017, Movement disorders : official journal of the Movement Disorder Society.

[24]  A. Hofman,et al.  Trends in the Incidence of Parkinson Disease in the General Population: The Rotterdam Study. , 2016, American journal of epidemiology.

[25]  Neng Wan,et al.  Parkinson's Disease and Pesticides Exposure: New Findings From a Comprehensive Study in Nebraska, USA. , 2016, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.

[26]  N. Jetté,et al.  The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis , 2016, Neuroepidemiology.

[27]  M. Quik,et al.  Nicotine as a potential neuroprotective agent for Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[28]  C. Tanner,et al.  Solvent exposures and parkinson disease risk in twins , 2012, Annals of neurology.

[29]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[30]  G. Miller,et al.  Parkinson's disease and pesticides: a toxicological perspective. , 2008, Trends in pharmacological sciences.

[31]  K. Marder,et al.  Pooled analysis of tobacco use and risk of Parkinson disease. , 2007, Archives of neurology.

[32]  P. S. St George-Hyslop,et al.  T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease. , 2006, Archives of neurology.

[33]  K. Bötzel,et al.  Prevalence and incidence of Parkinson's disease in Europe , 2005, European Neuropsychopharmacology.

[34]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[35]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[36]  R. Feldman,et al.  Environmental Toxins and Parkinson's Disease , 2005 .